



Dual Role of Act1 in Keratinocyte Differentiation and Host Defense: *TRAF3IP2* Silencing Alters Keratinocyte Differentiation and Inhibits IL-17 Responses

Sylviane Lambert¹, William R. Swindell^{1,2}, Lam C. Tsoi^{1,3}, Stefan W. Stoll¹ and James T. Elder^{1,4}

TRAF3IP2 is a candidate psoriasis susceptibility gene encoding Act1, an adaptor protein with ubiquitin ligase activity that couples the IL-17 receptor to downstream signaling pathways. We investigated the role of Act1 in keratinocyte responses to IL-17 using a tetracycline inducible short hairpin RNA targeting *TRAF3IP2*. Tetracycline exposure for 7 days effectively silenced *TRAF3IP2* mRNA and Act1 protein, resulting in 761 genes with significant changes in expression (495 down, 266 up; >1.5-fold, $P < 0.05$). Gene ontology analysis showed that genes affected by *TRAF3IP2* silencing are involved in epidermal differentiation, with early differentiation genes (*KRT1*, *KRT10*, *DSC1*, *DSG1*) being down-regulated and late differentiation genes (*SPRR2*, *SPRR3*, *LCE3*) being up-regulated. AP1 binding sites were enriched upstream of genes up-regulated by *TRAF3IP2* silencing. Correspondingly, nuclear expression of FosB and Fra1 was increased in *TRAF3IP2*-silenced cells. Many genes involved in host defense were induced by IL-17 in a *TRAF3IP2*-dependent fashion. Inflammatory differentiation conditions (serum addition for 4 days postconfluence) markedly amplified these IL-17 responses and increased basal levels and *TRAF3IP2* silencing-dependent up-regulation of multiple late differentiation genes. These findings suggest that *TRAF3IP2* may alter both epidermal homeostasis and keratinocyte defense responses to influence psoriasis risk.

Journal of Investigative Dermatology (2017) **137**, 1501–1511; doi:10.1016/j.jid.2016.12.032

INTRODUCTION

As a physical barrier that protects against exterior threats, our skin has developed a defensive system composed of both innate and acquired constituents (Gallo and Hooper, 2012; Pasparakis et al., 2014). Keratinocytes are the major cellular constituent of the epidermis, and they react to environmental and internal stimuli, making them major players in the regulation of skin inflammation through secretion of cytokines, chemokines, and antimicrobial peptides.

Several laboratories have implicated *TRAF3IP2* as a strong candidate gene for both psoriasis and psoriasis arthritis (Ellinghaus et al., 2010; Genetic Analysis of Psoriasis Consortium et al., 2010; Huffmeier et al., 2010; Stuart et al., 2015), with the single-nucleotide polymorphism rs33980500 changing aspartic acid to asparagine in the N-terminal region of the protein (D10N), possibly by altering its interactions with the molecular chaperone HSP90

(Wang et al., 2013). *TRAF3IP2* encodes Act1, also known as CIKS (Leonardi et al., 2000; Li et al., 2000; Morelli et al., 2000). Act1 is recruited to the IL-17 receptor through a SEFIR domain-mediated oligomerization and is essential for appropriate regulation of IL-17-mediated signaling (Chang et al., 2006; Qian et al., 2007).

TRAF proteins bind Act1, and TRAF6 is ubiquitinated by Act1 to mediate c-Jun N-terminal kinase and NF- κ B activation (Leonardi et al., 2000; Liu et al., 2009; Mauro et al., 2003; Morelli et al., 2000), whereas TRAF2 and TRAF5 regulate mRNA stability (Bulek et al., 2011; Sun et al., 2011). TRAF3 and TRAF4 negatively regulate IL-17 signaling by competing for Act1 binding with TRAF6 and IL17RA, respectively (Wu et al., 2015; Zepp et al., 2012; Zhu et al., 2010). Although IL-17 alone regulates the expression of a relatively small subset of approximately 40 genes in cultured keratinocytes (Chiricozzi et al., 2011; Nogales et al., 2008), biologics targeting IL-17 and its receptors are very effective treatments for psoriasis (Elyoussfi et al., 2016; Lowes et al., 2014).

Keratinocyte hyperproliferation and aberrant differentiation are hallmarks of psoriasis (Elder et al., 2010; Harden et al., 2015), and skin inflammation is associated with many of the same transcription factors (TFs) required for epidermal differentiation and barrier formation (i.e., AP1, Sp1, and KLF4) (Nakamura et al., 2007; Rossi et al., 1998; Segre et al., 1999; Tsoi et al., 2012; Uluckan et al., 2015). Genes expressed in the later stages of keratinocyte differentiation are frequently also involved in host defense (see Supplementary Table S1 online). Based on these

¹Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA; ²Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio, USA; ³Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA; and ⁴Ann Arbor Veterans Affairs Health System, Ann Arbor, Michigan, USA

Correspondence: James T. Elder, 7412 Medical Sciences Building I, 1301 East Catherine, Ann Arbor, Michigan 48109-5675, USA. E-mail: jelder@umich.edu

Abbreviations: qPCR, quantitative PCR; RNA-seq, high-throughput cDNA sequencing; Tet, tetracycline; TF, transcription factor; TNF- α , tumor necrosis factor- α

Received 30 August 2016; revised 8 December 2016; accepted 9 December 2016; accepted manuscript published online 6 March 2017

observations, we hypothesized that Act1 might play an important role in the response of differentiated keratinocytes to IL-17 relevant to the pathogenesis of psoriasis. To test this hypothesis, we assessed the effects of *TRAF3IP2* silencing under conditions promoting keratinocyte differentiation. Our results show that *TRAF3IP2* silencing increases expression of AP1 family TFs and several late keratinocyte differentiation genes in the absence of cytokine treatment and that *TRAF3IP2* is required for IL-17 induction of keratinocyte host defense genes, particularly when differentiation occurs in an inflammatory context.

RESULTS

To identify IL-17–induced genes affected by *TRAF3IP2* silencing, we engineered immortalized N/TERT-2G keratinocytes (Dickson et al., 2000) to inducibly express a short hairpin RNA targeting *TRAF3IP2* mRNA under the control of tetracycline (Tet) (Dickson et al., 2000; Stoll et al., 2010; Stoll et al., 2012). Seven days of silencing were necessary to effectively minimize Act1 protein expression (see [Supplementary Figure S1](#) online). During this interval, keratinocytes reached confluence, which is important for optimal cytokine responsiveness (Johnston et al., 2011). In preliminary experiments, we compared high (100 ng/ml) and low (10 ng/ml) doses of IL-17. As assessed by quantitative PCR (qPCR), we found that genes responding rapidly to IL-17 (e.g., *TNF*, *CCL20*, *CXCL1*, *IL1B*, *IL8*) were more strongly induced at the higher IL-17 concentration (see [Supplementary Figure S2a](#) online). However, we did not observe any significant expression differences in genes that respond more slowly to IL-17 (i.e., after 24 hours of stimulation) (e.g., *DEFB4*, *LCN2*, *S100A7-9*, *IL36G*) (see [Supplementary Figure S2b](#)). Based on these results, we selected a concentration of 10 ng/ml and a time point of 24 hours for high-throughput cDNA sequencing (RNA-seq) experiments.

TRAF3IP2 silencing affects keratinocyte differentiation

Using RNA-seq, we surveyed the effects of *TRAF3IP2* silencing on keratinocytes, either alone or in conjunction with IL-17 (10 ng/ml) and/or tumor necrosis factor- α (TNF- α , 10 ng/ml). Four independent RNA-seq experiments were performed on N/TERT-TR-sh*TRAF3IP2* cells. Unexpectedly, *TRAF3IP2* silencing on its own showed numerous changes in gene expression, with 266 genes up-regulated and 495 genes down-regulated (fold change > 1.5 or < 0.67, respectively; false discovery rate < 0.1) (see [Supplementary Tables S2](#) and [S3](#) online, respectively). We found the gene ontology biological process category “epidermis development” (GO:0008544) to be prominent in both the decreased and increased gene lists ($P = 1.58 \times 10^{-6}$ and $P = 7.05 \times 10^{-7}$, respectively) ([Figure 1a](#), and see [Supplementary Table S4](#) online). Early epidermal differentiation genes whose expression was decreased in *TRAF3IP2*-silenced keratinocytes included *KRT1* and *KRT10* (Fuchs and Green, 1980). Additional down-regulated genes of known relevance to keratinocyte differentiation were annotated for cell adhesion and included *DSC1* and *DSG1* (see [Supplementary Table S4b](#)). Validation of the same samples by qPCR confirmed their significantly reduced expression after *TRAF3IP2* silencing

([Figure 1b](#)). As shown by immunoblotting, Dsg1 and Krt10 proteins were also reduced by *TRAF3IP2* silencing in postconfluent keratinocytes ([Figure 1c](#)). These changes were reflected in the morphology of postconfluent keratinocytes, which displayed a more “cobblestone” appearance, with fewer large stratifying cells, after *TRAF3IP2* silencing ([Figure 1d](#)). Conversely, genes for which expression was up-regulated by *TRAF3IP2* silencing were involved in late epidermal differentiation (see [Supplementary Table S1](#)) and included *SPRR2A-E-G*, *SPRR3*, *LCE3D-E*, and *CNFN* (see [Supplementary Table S4a](#)). Confirmatory assessment of late differentiation gene expression in confluent *TRAF3IP2*-silenced keratinocytes showed a trend toward increased expression of *SPRR2A-C-D-E* and *SPRR3*, which reached significance when the cells were cultured to 4 days postconfluence to promote expression of late differentiation markers ([Figure 1e](#)). Culture to postconfluence also markedly increased expression of *LCE3D* and *LCE3E*, which showed a nonsignificant trend toward higher expression after *TRAF3IP2* silencing ([Figure 1e](#)).

We considered the possibility that *TRAF3IP2* silencing might affect proliferation, apoptosis, or cell attachment, thereby altering gene expression by affecting the degree of confluence. To this end, we investigated apoptosis ([Figure 2a](#)), cell counts ([Figure 2b](#)), and cell viability ([Figure 2c](#)) at different time points under standard attachment conditions and found them to be unaffected by *TRAF3IP2* silencing. *TRAF3IP2*-silenced keratinocytes also retained the same ability as control cells to express differentiation markers when subjected to nonadherent conditions known to induce differentiation (Watt, 1989; Watt et al., 1988) ([Figure 2d](#)). Although culture under nonadherent conditions decreased keratinocyte viability by approximately 20% and abrogated Ki-67 staining, there were no differences in these parameters when control and *TRAF3IP2*-silenced cells were compared ([Figure 2e](#) and [f](#)). Indicative of a lack of the nonspecific effects of Tet (Ahler et al., 2013), we observed no effects on expression of differentiation genes (see [Supplementary Figure S3a](#) online) or on cell growth (see [Supplementary Figure S3b](#)) in an N/TERT-derived line expressing an irrelevant short hairpin RNA targeting enhanced green fluorescent protein. Thus, we could not account for the observed *TRAF3IP2*-dependent differences in keratinocyte differentiation by confounding factors related to culture conditions.

We compared our RNA-seq results to inhibitory RNA-based transcriptome studies deposited in the Gene Expression Omnibus database (see [Supplementary Table S5](#) online) and found that genes modulated by *TRAF3IP2* silencing overlapped significantly with genes whose expression is altered by silencing of *KLF4*, a key TF regulating keratinocyte differentiation and barrier function during mouse skin development (Segre et al., 1999). Moreover, expression of *KLF4* was down-regulated by *TRAF3IP2* silencing, both in the RNA-seq data (fold change = 0.65, $P = .0085$) and by qPCR (fold change = 0.71, $P = .0007$). Other keratinocyte inhibitory RNA studies targeting *TP63*, *ZNF750*, *ANCR*, *ACTL6A*, and *EXOSC9* also manifested significant overlap with genes whose expression is modulated by *TRAF3IP2* silencing (see [Supplementary Table S5](#)). Each of these genes is involved in the control of epidermal differentiation (Bao et al., 2013;




Figure 1. TRAF3IP2-silenced keratinocytes display changes in epidermal differentiation-related gene expression. (a) Bar plot representing the percentage of genes down-regulated (black bars) or up-regulated (white bars) by *TRAF3IP2* silencing classified by biological processes. *P*-values are indicated within the bars. (b) Relative mRNA expression of *TRAF3IP2*, *KRT1*, *KRT10*, *DSC1*, and *DSG1* in N/TERT-TR-sh*TRAF3IP2* cells cultivated with or without Tet for 7 days. Bars represent mean + standard deviation of four independent experiments that were used for RNA-seq. **P* < 0.05 and ***P* < 0.001. (c) Immunoblot showing the abundance of Act1, Dsg1, and Krt10 in N/TERT-TR-sh*TRAF3IP2* cells cultivated with or without Tet until confluent (C) and at 2, 4, or 6 days after confluence. β -actin is shown to represent equal loading, and immunoblot is representative of two independent experiments. (d) Representative phase-contrast microphotographs of 4-day postconfluent control cells or *TRAF3IP2*-silenced cells. Scale bar = 20 μ m. (e) Relative expression of late differentiation gene mRNAs in N/TERT-TR-sh*TRAF3IP2* cells cultivated with or without Tet for 7 days (confluence), or subsequently brought to postconfluence in the presence or absence of Tet for an additional 4 days (post-confluent). Bars represent mean + standard deviation of three independent experiments that were used for RNA-seq. **P* < 0.05, ***P* < 0.001. Ctl, control; GO, gene ontology; sh, short hairpin; Tet, tetracycline.

Kretz et al., 2012; Mistry et al., 2012; Sen et al., 2012; Truong et al., 2006). Additionally, genes affected by *TRAF3IP2* silencing significantly overlapped with genes regulated in suprabasal versus basal epidermis (see [Supplementary Table S5](#)) (Gulati et al., 2013).

We used semiparametric generalized additive logistic models (Swindell et al., 2013) to ask whether TF binding motifs within promoter regions were enriched as a function of *TRAF3IP2* silencing. This analysis showed significant enrichment for AP1 motifs within 2 kilobase pairs upstream of the transcription start sites of genes up-regulated by *TRAF3IP2* silencing (Figure 3a, and see [Supplementary Table S6](#) online). In pursuit of this observation, we measured the expression of various AP1 family members in

TRAF3IP2-silenced cells by qPCR and Western blotting. We found that *FOSB* and *FOSL1* mRNA levels were elevated (fold change = 1.87 and 2.20, respectively; *P* = .0484 and .0030, respectively) (Figure 3b), as were the corresponding FosB and Fra1 protein levels in nuclear extracts (Figures 3c and 3d).

TRAF3IP2 silencing has prominent effects on the induction of host defense and *SPRR2* family genes by IL-17

Our RNA-seq experiment included stimulation by IL-17, TNF- α , or both. A Venn diagram summarizing the overall results of this experiment is presented in [Supplementary Figure S4](#) online. Consistent with prior results of others (Chiricozzi et al., 2011), many more genes were modulated by TNF- α alone or IL-17 in conjunction with TNF- α than by




Figure 2. Inhibition of differentiation in *TRAF3IP2*-silenced keratinocyte is not due to changes in cell proliferation or viability. (a, b) Flow cytometry analysis of N/TERT-TR-sh*TRAF3IP2* cultured in the presence (black) or not (white) of Tet for the indicated time. Cells were stained for annexin V and propidium iodide and assessed for (a) annexin V staining or (b) cell counts. Result represents mean + standard deviation of four independent experiments. (c) N/TERT-TR-sh*TRAF3IP2* cells were cultured for the indicated amount of time with (white) or without Tet (black) and then incubated in presence of a resazurin compound. Reduction of the resazurin was measured in the same cultures over a period of 8 days. Result represents mean ± standard deviation of four independent experiments. (d) Quantitative PCR analysis of differentiation genes induced in N/TERT-TR-sh*TRAF3IP2* cells seeded in poly-HEMA-coated plates in the presence (black) or not (white) of Tet. Results represent mean + standard deviation of three independent experiments. Cells were also seeded in noncoated dish (Ctl) to show the induction of differentiation gene expression induced by suspension. (e, f) Flow cytometry analysis of cell viability and Ki-67 expression after being seeded on poly-HEMA-coated or normal dishes for 24 hours in the presence (white) or absence (black) of Tet. Results are expressed as percentage of live cells or mean fluorescent units (MFI). Ctl, control; sh, short hairpin; Tet, tetracycline.

IL-17 alone. Herein, we focus on the effects of *TRAF3IP2* silencing on IL-17 stimulation, for which Act1 is known to be a direct downstream mediator (Chang et al., 2006; Sonder et al., 2011).

RNA-seq identified 38 up-regulated and 45 down-regulated genes in response to IL-17 in control cells (see Supplementary Figure S4). Three microarray-based publications investigating the effects of IL-17 in monolayer normal human keratinocytes were identified in the Gene Expression Omnibus database, and each of them manifested highly significant overlap with our results (Chiricozzi et al., 2011; Nogales et al., 2008; Swindell et al., 2012) (see Supplementary Table S7 online). Supplementary Table S8 online presents fold change expression values for all genes in the RNA-seq experiment displaying significantly altered expression in response to IL-17 in control cells, compared with their expression in *TRAF3IP2*-silenced keratinocytes.

Gene Ontology biological process term enrichment analysis of transcripts up-regulated by IL-17 in control keratinocytes implicated genes annotated for host defense responses (see Supplementary Table S1), including *CAMP*, *CCL20*, *ELF3*, *NFKBIZ*, *SAA1*, *S100A7-9-12*, and *VNN1* (Figure 4a, and see Supplementary Table S9 online). The induction of host defense-related genes by IL-17 was markedly blunted in

TRAF3IP2-silenced cells, with the result that no host defense annotations remained significant after silencing (Figure 4b, and see Supplementary Table S9). Genes involved in late keratinocyte differentiation were also induced by IL-17 in control cells, including multiple *SPRR2* family members, *LCE3D*, *LCE3E*, and *SPRR3*. We confirmed by qPCR that multiple host defense genes, including *CXCL2*, *DEFB4*, *IL36G*, *LCN2*, *NFKBIZ*, *S100A7-8-9-12*, *SAA1*, *SAA2*, and *ZC3H12A*, were significantly induced by IL-17 in a *TRAF3IP2*-dependent fashion (Figure 4c, and see Supplementary Figure S5 online for all genes tested by qPCR). Transient transfection of N/TERT keratinocytes with two different short hairpin RNAs (both different from that used in the lentiviral construct) confirmed the specificity of the effect of *TRAF3IP2* silencing on IL-17 responses (see Supplementary Figure S3c). Protein secretion analysis showed significant reduction of human β -defensin-2 (encoded by *DEFB4*), lipocalin-2, IL-8, and *CXCL1* protein levels in cells silenced for *TRAF3IP2* (Figure 4f). We also confirmed that multiple *SPRR2* genes were induced by IL-17, and for all of them except *SPRR2D*, induction was significantly blunted by *TRAF3IP2* silencing (Figure 4d). However, we were unable to confirm IL-17 induction of *LCE3D*, *LCE3E*, or *SPRR3* in either control or *TRAF3IP2*-silenced cells (see Supplementary Figure S5a). Finally, the early differentiation genes *KRT1*,




Figure 3. TRAF3IP2 silencing increases enrichment of binding motifs and expression of differentiation-related TFs. (a) Bar plots depicting the top 10 Z-scores for TF/transcriptional cofactor binding motifs in the 2-kilobase pair promoter of genes up-regulated (black) or down-regulated (white) in *TRAF3IP2*-silenced cells. *P*-values are indicated in the bars. (b) Relative gene expression of AP1 TF subunits in Ctl or sh*TRAF3IP2* cells. Results are mean + SD of three independent experiments. **P* < 0.05, ***P* < 0.005. (c) Protein abundance of AP1 subunits in cytoplasmic or nuclear extract of Ctl or sh*TRAF3IP2* cells. Purity of cytoplasmic and nuclear fractions was assessed by detection of IκBα (cytoplasmic) and lamin A/C (nuclear). Blots are representative of four experiments. (d) Relative abundance of AP1 subunit nuclear proteins, normalized to lamin A/C. Results are expressed as the base 10 logarithm of fold change between Ctl and sh*TRAF3IP2* from four independent experiments, of which one is shown in c. Ctl, control; Cyto, cytoplasmic extract; Nucl, nuclear extract; sh, short hairpin; TF, transcription factor.

KRT10, *DSG1*, and *DSC1* were not significantly altered by IL-17 treatment (Figure 4e).

Psoriatic epidermis in vivo manifests a distinctive differentiation program known as *regenerative maturation*, which is also seen in wound healing (Gottlieb et al., 1992; Mansbridge et al., 1984). We approximated a similar state of inflammatory differentiation in vitro by growing keratinocytes to 4 days postconfluence in the presence of serum, as previously described (Van Ruissen et al., 1996). As shown in Figure 5a, expression of the early differentiation markers *KRT1*, *KRT10*, *DSC1*, and *DSG1* were markedly reduced under inflammatory differentiation conditions relative to confluent cells. As already noted for IL-17 stimulation experiments performed at confluence (Figure 4), these genes were not induced in response to IL-17 under inflammatory differentiation conditions and, with the exception of *KRT10*, were further reduced in *TRAF3IP2*-silenced cells. In contrast, the late differentiation genes *LCE3D*, *LCE3E*, *SPRR2A-C-D-E*, and *SPRR3* were expressed at much higher levels in keratinocytes exposed to serum for 4 days postconfluence relative to confluent controls without serum (Figure 5b). Several late differentiation genes were further induced in response to *TRAF3IP2* silencing under these conditions, including *LCE3D*, *LCE3E*, *SPRR2A*, and *SPRR2E* (Figure 5b).

We then examined the effects of *TRAF3IP2* silencing on transcripts induced by IL-17 in the context of inflammatory differentiation. Multiple host defense genes (*CCL20*, *CXCL1*, *DEFB4*, *IL36G*, *NFKBIZ*, *LCN2*, *SAA1*, *SAA2*, *S100A7-8-9-12*, and *ZC3H12A*) were much more strongly induced by IL-17 under inflammatory differentiation conditions

compared with confluent cells, and all of these inductions were blocked by *TRAF3IP2* silencing (Figure 5c, and see Supplementary Figure S6 online for all genes tested). Although *SPRR2A*, *-2B*, *-2E*, and *-2F* were also induced by IL-17 under inflammatory differentiation conditions, only the inductions of *SPRR2A* and *SPRR2F* were significantly inhibited by *TRAF3IP2* silencing (Figure 5b).

DISCUSSION

The physiological importance of Act1 is reflected in its ability to interact with multiple signaling pathways downstream of the IL-17 receptor (Gaffen, 2009; Gu et al., 2013; Linden, 2007; Wu et al., 2012) and its role in a variety of inflammatory pathologies (Claudio et al., 2009; Kang et al., 2010; Pisitkun et al., 2010, 2012; Qian et al., 2008; Swaidani et al., 2011; Weaver et al., 2013; Wu et al., 2012; Zepp et al., 2011). *TRAF3IP2* resides in a known susceptibility locus for inflammatory diseases such as psoriasis and psoriasis arthritis (Ellinghaus et al., 2010; Genetic Analysis of Psoriasis Consortium et al., 2010; Huffmeier et al., 2010), Crohn's disease (Ciccacci et al., 2013) and type 1 diabetes (Bergholdt et al., 2012). Moreover, IL-17 and its receptor are specific therapeutic targets in psoriasis (Lowes et al., 2014; Martin et al., 2013).

Nearly all studies aiming to elucidate the function of Act1, including the report of a spontaneous mutation leading to an atopic dermatitis-like phenotype, and the effects of the psoriasis-related Act1(D10N) on T helper type 17-cell hyperactivity, have been performed in mouse models (Matsushima et al., 2010; Wang et al., 2013). Little is thus


Figure 4. TRAF3IP2 silencing affects IL-17–induced genes involved in host defense and keratinocyte differentiation. (a, b) Bar plots

representing the percentage of IL-17–induced genes associated with various gene ontology BP terms related to keratinocyte differentiation (black) or host defense (white) in (a) control cells or (b) *TRAF3IP2*-silenced cells.

P-values are indicated within the bars.

(c–e) Quantitative PCR analysis of N/TERT-TR-sh*TRAF3IP2* cells stimulated with phosphate-buffered saline (black bars) or with IL-17 (10 ng/ml, white bars) for 24 hours after growth to confluence in the presence or absence of Tet. (c) Genes involved in host defense responses. (d) Late and (e) early keratinocyte differentiation genes. Bars represent mean + standard deviation of three experiments, which were independent from the ones used for RNA-seq (**P* < 0.05, ***P* < 0.01, ****P* < 0.005).

Asterisks over open bars indicate significance with respect to IL-17 treatment; asterisks over horizontal lines indicate significance with respect to *TRAF3IP2* silencing. (f) ELISA measurement of protein secretion in the supernatant during 24 hours of IL-17 stimulation in presence or absence of Tet. Graphs represent mean + SD of three independent experiments. **P* < 0.05, ***P* < 0.01 and ****P* < 0.005. BP, biological process; Ctl, control; GO, Gene Ontology; RNA-seq, high-throughput cDNA sequencing; sh, short hairpin; Tet, tetracycline.






Figure 5. *TRAF3IP2* silencing in an inflammatory environment preferentially affects IL-17–induced genes involved in host defense, compared with epidermal differentiation genes. N/TERT-TR-sh*TRAF3IP2* cells were stimulated with IL-17 (10 ng/ml, 24 hours) when confluent or after being kept for 4 days postconfluence in the presence of FBS. Expression of genes related to (a) early keratinocyte differentiation, (b) late differentiation, or (c) host defense was then assessed by quantitative PCR. Graphs represent mean + standard deviation of three independent experiments. *P*-values are designated as follows. °*P* < 0.05, °°*P* < 0.005 for IL-17 stimulation versus controls. **P* < 0.05, ***P* < 0.005, and ****P* < 0.001 in *TRAF3IP2*-silenced versus nonsilenced cells. Δ*P* < 0.05, ΔΔ*P* < 0.001 relative to expression at confluence versus postconfluence + FBS. Ctl, control; FBS, fetal bovine serum; ns, not significant; sh, short hairpin.

known about the role of Act1 in humans, with the exception of one report on the loss of IL-17 responses in human chronic mucocutaneous candidiasis resulting from a different Act1 mutation (T536I) (Boisson et al., 2013). To address this gap, we used RNA-seq to identify genes whose expression was affected by *TRAF3IP2* silencing in human keratinocytes and then followed up on those studies using qPCR.

***TRAF3IP2* silencing differentially affects early and late keratinocyte differentiation genes**

Even though monolayer keratinocyte cultures do not faithfully replicate the physiology of intact skin (Klingenberg et al., 2010), confluent keratinocytes manifest many aspects of the terminal differentiation program (Kolly et al., 2005; Poumay et al., 1999; Poumay and Pittelkow, 1995). Using this model system (Figure 1), we found that *TRAF3IP2* silencing reshapes differentiation-related gene expression by markedly reducing the expression of the early differentiation genes *KRT1*, *KRT10*, *DSC1*, and *DSG1* (Figure 1b), yielding a more “cobblestone” and less stratified phenotype (Figure 1d). In contrast, late differentiation genes of the *SPRR2*, *SPRR3*, and *LCE3* families were up-regulated after *TRAF3IP2* silencing, depending on the differentiation context (Figures 1e and 5b). This biphasic phenotype is reminiscent of Krt1/Krt10-knockout mice, which manifest markedly reduced Dsg1 and Dsc1 protein levels but retain effective epidermal barrier function (Wallace et al., 2012). We found that *TRAF3IP2*-responsive genes overlapped significantly with genes regulated in suprabasal epidermis versus normal skin (Gulati et al., 2013) and genes regulated by *KLF4*, *ZNF750*, *ANCR*, *ACTL6A*, and *EXOSC9*, which have all been implicated in epidermal differentiation (Bao et al., 2013; Kretz et al., 2012; Mistry et al., 2012; Sen et al., 2012; Truong et al., 2006) (Table S5), further suggesting a role in keratinocyte differentiation.

Analysis of TF binding sites among genes up-regulated by *TRAF3IP2* silencing showed significant enrichment of motifs for members of the AP1 family (Figure 2a), and correspondingly, we found AP1 family members FosB and Fra1 to be more highly expressed in *TRAF3IP2*-silenced keratinocytes (Figure 2c and d). It is difficult to extrapolate these globally derived results to individual genes because of varying promoter structures, trans-acting factors, and chromatin configurations. Nevertheless, given that AP1 sites are present in most *SPRR2* genes (Cabral et al., 2001) and that AP1 suppresses expression of *KRT1* and *KRT10* in keratinocytes (Rutberg et al., 2000), it is tempting to speculate that both increased expression of late differentiation genes and decreased expression of early differentiation genes might be mediated by increased AP1 activity in the context of *TRAF3IP2* silencing. In the in vivo context of psoriasis, we have shown that noncoding single-nucleotide polymorphisms residing near psoriasis genome-wide association study signals frequently disrupt AP1 binding sites (Swindell et al., 2015). Given that genes whose expression was altered by *TRAF3IP2* silencing were also enriched for TF binding sites other than those belonging to the AP1 family (Figure 3a), and that the profile of genes affected by *TRAF3IP2* silencing overlap with responses to silencing of other TFs in keratinocytes (see Supplementary Table S5), it is

likely that TFs outside the AP1 family may also be involved in mediating the effects of *TRAF3IP2* silencing.

Because gene expression patterns change substantially as keratinocytes pass through confluence (Kolly et al., 2005; Paragh et al., 2010; Radoja et al., 2006; Tran et al., 2012) or are separated from their substratum (Banno and Blumenberg, 2014), it was important to rule out *TRAF3IP2*-related differences in response to cell proliferation, death, or detachment, which might affect the confluence of the cultures. Keratinocyte apoptosis was not detectably influenced by *TRAF3IP2* silencing (Figure 2a), nor was cell growth (Figure 2b and c). *TRAF3IP2* silencing also did not affect the differentiation process in cells subjected to suspension culture (Figure 2d), suggesting that the *TRAF3IP2*-dependent effects we have observed require cell-substratum contact.

***TRAF3IP2*-dependent effects of IL-17 on host defense genes are potentiated by keratinocyte differentiation in an inflammatory environment**

Consistent with our observation that confluent keratinocyte monolayers display increased responsiveness to cytokine stimulation compared with subconfluent keratinocytes (Johnston et al., 2011), stratified keratinocytes in a reconstituted human epidermis model have been shown to be substantially more sensitive to IL-17 compared with monolayer keratinocytes (Chiricozzi et al., 2014). Our use of confluent cultures may help explain why we identified a similar number of genes influenced by IL-17 treatment as previous studies, despite using a lower IL-17 concentration (10 ng/ml vs. 100–200 ng/ml in previous studies) (see Supplementary Table S7).

Given that an important function of differentiated keratinocytes is to provide a physical barrier to external threats while acting as the earliest sentinel for innate immunity, it is not surprising that IL-17-inducible genes were involved in both host defense and some late keratinocyte differentiation responses (Figures 4 and 5, and see Supplementary Table S9) (Li et al., 2014). Multiple host defense genes were strongly induced by IL-17 in a *TRAF3IP2*-dependent fashion under confluent conditions (Figure 4), even more so in the context of inflammatory differentiation (Figure 5). We also confirmed IL-17 inducibility of several late differentiation genes belonging to the *SPRR2* family (Figures 4 and 5). In contrast, the early differentiation genes *KRT1*, *KRT10*, *DSG1*, and *DSC1* were unresponsive to IL-17 (Figure 4) and markedly down-regulated under inflammatory differentiation conditions, with additional declines after *TRAF3IP2* silencing (Figure 5a).

Overall, then, the effect of *TRAF3IP2* silencing is to decrease expression of early differentiation genes and increase expression of late differentiation genes under basal conditions, as well as inhibit host defense responses to IL-17. We do not believe that the loss of IL-17 responses after *TRAF3IP2* silencing is secondary to a differentiation block, because many late differentiation genes are actually expressed at higher levels after *TRAF3IP2* silencing, rather than lower levels as would be predicted for a differentiation block. Rather, we would suggest that because (i) keratinocytes are increasingly exposed to the microbial environment as they mature, (ii) IL-17 is implicated in host responses to a

variety of pathogens [reviewed in Huppler and Gaffen, 2016], (iii) differentiated keratinocytes manifest enhanced responsiveness to IL-17 (Chiricozzi et al., 2014), and (iv) Act1 is a well-established downstream mediator of IL-17 action (Chang et al., 2006, Qian et al., 2007), Act1 plays an increasingly important role in mediating IL-17 responses to the microbial environment as keratinocytes become more terminally differentiated.

The *SPRR2* genes were distinctive among the late differentiation genes in that they were inducible by both IL-17 and *TRAF3IP2* silencing. Correspondingly, they also appear to function in both host defense and late differentiation, because they are involved in both cornified envelope formation and antioxidant defense (Vermeij et al., 2011, Vermeij and Backendorf, 2010). Despite their similarity in structure, the *SPRR2* genes manifest different patterns of tissue-specific and stimulus-specific expression involving variation in promoter elements (Cabral et al., 2001). The fact that these genes display different patterns of responsiveness to IL-17 under inflammatory differentiation conditions (Figure 5) suggests that they have evolved different regulatory signals to adapt to various stimuli.

Act1 and psoriasis pathogenesis: possible dual roles in epidermal homeostasis and inflammation

It remains mysterious how a putative loss-of-function variant of Act1 (the D10N variation) is associated with increased risk of psoriasis and psoriatic arthritis (Ellinghaus et al., 2010; Huffmeier et al., 2010). Act1 is a multidomain protein with multiple downstream effectors (Wu et al., 2012), and it is speculative to equate Act1 knockdown in our experiment with loss of function from the D10N mutation. However, loss of Act1 function (whether due to the D10N mutation or to other more indirect mechanisms) might explain the increased expression of late differentiation genes that is characteristic of psoriasis (Li et al., 2014). The most highly up-regulated gene co-expression module that we identified in psoriatic lesions (module P26) (i) contained all of the *SPRR2B* genes (Li et al., 2014), many of which were induced by Act1 silencing in highly differentiated cells (Figure 2e) and also inducible by IL-17 in an Act1-dependent fashion (Figures 4d and 5b), and (ii) showed strong overlap with genes expressed in differentiated versus basal epidermis as well as genes affected by silencing of the key epidermal regulators *STAU*, *TINCR*, *ZNF750*, and *KLF4* (Li et al., 2014). However, this aspect of *TRAF3IP2* function cannot account for the increased expression of many IL-17–induced host defense genes in psoriasis, because a loss-of-function mutation would be expected to decrease, rather than increase, expression of these genes. As might be expected given its key role in inflammation, IL-17 signaling is subject to several levels of feedback regulation (Garg et al., 2013), including one involving the ribonuclease MCP1P1 encoded by *ZC3H12A* (Garg et al., 2015). *TRAF3IP2* silencing markedly inhibits the expression of *ZC3H12A* (Figures 4 and 5), which might be expected to relax this negative feedback regulation. Although further studies are needed to understand the mechanistic function of *TRAF3IP2* in keratinocytes and the complex role of the Act1D10N mutation in keratinocytes with respect to the pathogenesis of psoriasis, our findings concur with others

linking the processes of late keratinocyte differentiation and host defense (Akiyama et al., 2014; Gutowska-Owsiak et al., 2012) and suggest a role for *TRAF3IP2* in the integration of these processes.

MATERIALS AND METHODS

Immortalized N/TERT-2G keratinocytes expressing a Tet operator were stably infected with a lentivirus coding for a short hairpin RNA directed against the 3' untranslated region of *TRAF3IP2* mRNA to create N/TERT-TR-sh*TRAF3IP2* cells, as previously described (Stoll et al., 2010). To silence *TRAF3IP2*, these cells were treated with 1 µg/ml Tet, typically for 7 days, with feeding every 2 days.

RNA-seq libraries were prepared using the Illumina mRNA-Seq kit (Illumina, San Diego, CA) and analyzed as described previously (Li et al., 2014). Gene ontology analysis of RNA-seq data was performed using DAVID (Database for Annotation, Visualization and Integrated Discovery, available at <http://david.abcc.ncifcrf.gov>) (Huang da et al., 2009). RNA-seq results have been submitted to the Gene Expression Omnibus database (GSE86451). For qPCR experiments, total RNA was isolated using RNeasy plus kit (Qiagen, Valencia, CA) followed by reverse transcription (High-Capacity cDNA Reverse Transcription kit, Applied Biosystems, Foster City, CA) and qPCR on an ABI PRISM 7900HT system (Applied Biosystems). Statistical analysis of qPCR data was performed using Prism (GraphPad, La Jolla, CA) with two-tailed *t* tests with Bonferroni correction for multiple comparison testing of different experimental conditions, as appropriate. Additional methodological details are described in the Supplementary Materials online.

CONFLICT OF INTEREST

The authors state no conflict of interest.

ACKNOWLEDGMENTS

We thank James Rheinwald for providing the N/TERT-2G keratinocyte cell line. This work was supported by the National Institute of Arthritis, Musculoskeletal, and Skin Diseases, National Institutes of Health (R01AR052889, R01AR054966, R01AR062382, and R01AR065183 to JTE; K01AR050462 and R03 AR049420 to SWS), by awards from the American Skin Association (SL), the National Psoriasis Foundation (SWS and LCT), the Dermatology Foundation (WRS and LCT), the Arthritis National Research Foundation (LCT), the Dermatology Foundation (WRS), and the Babcock Memorial Trust. JTE is supported by the Ann Arbor Veterans Administration Hospital.

SUPPLEMENTARY MATERIAL

Supplementary material is linked to the online version of the paper at www.jidonline.org, and at <http://dx.doi.org/10.1016/j.jid.2016.12.032>.

REFERENCES

- Ahler E, Sullivan WJ, Cass A, Braas D, York AG, Bensinger SJ, et al. Doxycycline alters metabolism and proliferation of human cell lines. *PLoS One* 2013;8:e64561.
- Akiyama T, Niyonsaba F, Kiatsurayanon C, Nguyen TT, Ushio H, Fujimura T, et al. The human cathelicidin LL-37 host defense peptide upregulates tight junction-related proteins and increases human epidermal keratinocyte barrier function. *J Innate Immun* 2014;6:739–53.
- Banno T, Blumenberg M. Keratinocyte detachment-differentiation connection revisited, or anoikis-pityriasis nexus redux. *PLoS One* 2014;9(6):e100279.
- Bao X, Tang J, Lopez-Pajares V, Tao S, Qu K, Crabtree GR, et al. ACTL6a enforces the epidermal progenitor state by suppressing SWI/SNF-dependent induction of KLF4. *Cell Stem Cell* 2013;12:193–203.
- Bergholdt R, Brorsson C, Palleja A, Berchtold LA, Floyel T, Bang-Berthelsen CH, et al. Identification of novel type 1 diabetes candidate genes by integrating genome-wide association data, protein-protein interactions, and human pancreatic islet gene expression. *Diabetes* 2012;61:954–62.
- Boisson B, Wang C, Pedergnana V, Wu L, Cypowyj S, Rybojad M, et al. An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. *Immunity* 2013;39:676–86.

- Bulek K, Liu C, Swaidani S, Wang L, Page RC, Gulen MF, et al. The inducible kinase IKK α is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation. *Nature Immunol* 2011;12:844–52.
- Cabral A, Voskamp P, Cleton-Jansen AM, South A, Nizetic D, Backendorf C. Structural organization and regulation of the small proline-rich family of cornified envelope precursors suggest a role in adaptive barrier function. *J Biol Chem* 2001;276:19231–7.
- Chang SH, Park H, Dong C. Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. *J Biol Chem* 2006;281:35603–7.
- Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, Nogales KE, Tian S, Cardinale I, et al. Integrative responses to IL-17 and TNF- α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. *J Invest Dermatol* 2011;131:677–87.
- Chiricozzi A, Nogales KE, Johnson-Huang LM, Fuentes-Duculan J, Cardinale I, Bonifacio KM, et al. IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model. *PLoS One* 2014;9(2):e90284.
- Ciccacci C, Biancone L, Di Fusco D, Ranieri M, Condino G, Giardina E, et al. TRAF3IP2 gene is associated with cutaneous extraintestinal manifestations in inflammatory bowel disease. *J Crohns Colitis* 2013;7:44–52.
- Claudio E, Sonder SU, Saret S, Carvalho G, Ramalingam TR, Wynn TA, et al. The adaptor protein CIKS/Act1 is essential for IL-25-mediated allergic airway inflammation. *J Immunol* 2009;182(3):1617–30.
- Dickson MA, Hahn WC, Ino Y, Ronfard V, Wu JY, Weinberg RA, et al. Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. *Mol Cell Biol* 2000;20:1436–47.
- Elder JT, Bruce AT, Gudjonsson JE, Johnston A, Stuart PE, Tejasvi T, et al. Molecular dissection of psoriasis: integrating genetics and biology. *J Invest Dermatol* 2010;130:1213–26.
- Ellinghaus E, Ellinghaus D, Stuart PE, Nair RP, Debrus S, Raelson JV, et al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. *Nat Genet* 2010;42:991–5.
- Elyoussfi S, Thomas BJ, Ciurtin C. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies. *Rheumatol Int* 2016;36:603–12.
- Fuchs E, Green H. Changes in keratin gene expression during terminal differentiation of the keratinocyte. *Cell* 1980;19:1033–42.
- Gaffen SL. Structure and signalling in the IL-17 receptor family. *Nat Rev Immunol* 2009;9:556–67.
- Gallo RL, Hooper LV. Epithelial antimicrobial defence of the skin and intestine. *Nat Rev Immunol* 2012;12:503–16.
- Garg AV, Ahmed M, Vallejo AN, Ma A, Gaffen SL. The deubiquitinase A20 mediates feedback inhibition of interleukin-17 receptor signaling. *Sci Signal* 2013;6(278):ra44.
- Garg AV, Amatya N, Chen K, Cruz JA, Grover P, Whibley N, et al. MCP1 Endoribonuclease activity negatively regulates interleukin-17-mediated signaling and inflammation. *Immunity* 2015;43:475–87.
- Genetic Analysis of Psoriasis Consortium, the Wellcome Trust Case Control Consortium 2, Strange A, Capon F, Spencer CC, Knight J, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. *Nat Genet* 2010;42(11):985–90.
- Gottlieb AB, Grossman RM, Khandke L, Carter DM, Sehgal PB, Fu SM, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. *J Invest Dermatol* 1992;98:302–9.
- Gu C, Wu L, Li X. IL-17 family: cytokines, receptors and signaling. *Cytokine* 2013;64:477–85.
- Gulati N, Krueger JG, Suarez-Farinas M, Mitsui H. Creation of differentiation-specific genomic maps of human epidermis through laser capture microdissection. *J Invest Dermatol* 2013;133:2640–2.
- Gutowska-Owsiak D, Schaupp AL, Salimi M, Selvakumar TA, McPherson T, Taylor S, et al. IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion. *Exp Dermatol* 2012;21:104–10.
- Harden JL, Krueger JG, Bowcock AM. The immunogenetics of psoriasis: A comprehensive review. *J Autoimmun* 2015;64:66–73.
- Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* 2009;4:44–57.
- Huffmeier U, Uebe S, Ekici AB, Bowes J, Giardina E, Korendowycz E, et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. *Nat Genet* 2010;42:996–9.
- Huppler AR, Gaffen SL. Editorial: fake it 'til you make it: mast cells acquire IL-17 exogenously. *J Leukoc Biol* 2016;100:445–6.
- Johnston A, Gudjonsson JE, Aphale A, Guzman AM, Stoll SW, Elder JT. EGFR and IL-1 signaling synergistically promote keratinocyte antimicrobial defenses in a differentiation-dependent manner. *J Invest Dermatol* 2011;131:329–37.
- Kang Z, Altuntas CZ, Gulen MF, Liu C, Giltiay N, Qin H, et al. Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis. *Immunity* 2010;32:414–25.
- Klingenberg JM, McFarland KL, Friedman AJ, Boyce ST, Aronow BJ, Supp DM. Engineered human skin substitutes undergo large-scale genomic reprogramming and normal skin-like maturation after transplantation to athymic mice. *J Invest Dermatol* 2010;130:587–601.
- Kolly C, Suter MM, Muller EJ. Proliferation, cell cycle exit, and onset of terminal differentiation in cultured keratinocytes: pre-programmed pathways in control of C-Myc and Notch1 prevail over extracellular calcium signals. *J Invest Dermatol* 2005;124:1014–25.
- Kretz M, Webster DE, Flockhart RJ, Lee CS, Zehnder A, Lopez-Pajares V, et al. Suppression of progenitor differentiation requires the long noncoding RNA ANCR. *Genes Dev* 2012;26:338–43.
- Leonardi A, Chariot A, Claudio E, Cunningham K, Siebenlist U. CIKS, a connection to Ikappa B kinase and stress-activated protein kinase. *Proc Natl Acad Sci USA* 2000;97:10494–9.
- Li B, Tsoi LC, Swindell WR, Gudjonsson JE, Tejasvi T, Johnston A, et al. Transcriptome analysis of psoriasis in a large case-control sample: RNA-seq provides insights into disease mechanisms. *J Invest Dermatol* 2014;134:1828–38.
- Li X, Commane M, Nie H, Hua X, Chatterjee-Kishore M, Wald D, et al. Act1, an NF-kappa B-activating protein. *Proc Natl Acad Sci USA* 2000;97:10489–93.
- Linden A. A role for the cytoplasmic adaptor protein Act1 in mediating IL-17 signaling. *Science's STKE: signal transduction knowledge environment* 2007; 2007;2007(398):re4.
- Liu C, Qian W, Qian Y, Giltiay NV, Lu Y, Swaidani S, et al. Act1, a U-box E3 ubiquitin ligase for IL-17 signaling. *Sci Signal* 2009;2(92):ra63.
- Lowes MA, Suarez-Farinas M, Krueger JG. Immunology of psoriasis. *Annu Rev Immunol* 2014;32:227–55.
- Mansbridge JN, Knapp AM, Streffling AM. Evidence for an alternative pathway of keratinocyte maturation in psoriasis from an antigen found in psoriatic but not normal epidermis. *J Invest Dermatol* 1984;83:296–301.
- Martin DA, Towne JE, Kricorian G, Klekotka P, Gudjonsson JE, Krueger JG, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. *J Invest Dermatol* 2013;133:17–26.
- Matsushima Y, Kikkawa Y, Takada T, Matsuoka K, Seki Y, Yoshida H, et al. An atopic dermatitis-like skin disease with hyper-IgE-emia develops in mice carrying a spontaneous recessive point mutation in the Traf3ip2 (Act1/CIKS) gene. *J Immunol* 2010;185:2340–9.
- Mauro C, Vito P, Mellone S, Pacifico F, Chariot A, Formisano S, et al. Role of the adaptor protein CIKS in the activation of the IKK complex. *Biochem Biophys Res Commun* 2003;309:84–90.
- Mistry DS, Chen Y, Sen GL. Progenitor function in self-renewing human epidermis is maintained by the exosome. *Cell Stem Cell* 2012;11:127–35.
- Morelli C, Magnanini C, Mungall AJ, Negrini M, Barbanti-Brodano G. Cloning and characterization of two overlapping genes in a subregion at 6q21 involved in replicative senescence and schizophrenia. *Gene* 2000;252(1–2):217–25.
- Nakamura Y, Kawachi Y, Xu X, Sakurai H, Ishii Y, Takahashi T, et al. The combination of ubiquitous transcription factors AP-1 and Sp1 directs keratinocyte-specific and differentiation-specific gene expression in vitro. *Exp Dermatol* 2007;16:143–50.

- Nogral KE, Zaba LC, Guttman-Yassky E, Fuentes-Duculan J, Suarez-Farinas M, Cardinale I, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. *Br J Dermatol* 2008;159:1092–102.
- Paragh G, Ugocsai P, Vogt T, Schling P, Kel AE, Tarabin V, et al. Whole genome transcriptional profiling identifies novel differentiation regulated genes in keratinocytes. *Exp Dermatol* 2010;19:297–301.
- Pasparakis M, Haase I, Nestle FO. Mechanisms regulating skin immunity and inflammation. *Nat Rev Immunol* 2014;14:289–301.
- Pisitkun P, Claudio E, Ren N, Wang H, Siebenlist U. The adaptor protein CIKS/ACT1 is necessary for collagen-induced arthritis, and it contributes to the production of collagen-specific antibody. *Arthritis Rheum* 2010;62:3334–44.
- Pisitkun P, Ha HL, Wang H, Claudio E, Tivy CC, Zhou H, et al. Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis. *Immunity* 2012;37:1104–15.
- Poumay Y, Jolivet G, Pittelkow MR, Herphelin F, De Potter IY, Mitev V, et al. Human epidermal keratinocytes upregulate expression of the prolactin receptor after the onset of terminal differentiation, but do not respond to prolactin. *Arch Biochem Biophys* 1999;364:247–53.
- Poumay Y, Pittelkow MR. Cell density and culture factors regulate keratinocyte commitment to differentiation and expression of suprabasal K1/K10 keratins. *J Invest Dermatol* 1995;104:271–6.
- Qian Y, Giltaiy N, Xiao J, Wang Y, Tian J, Han S, et al. Deficiency of Act1, a critical modulator of B cell function, leads to development of Sjogren's syndrome. *Eur J Immunol* 2008;38:2219–28.
- Qian Y, Liu C, Hartupree J, Altuntas CZ, Gulen MF, Jane-Wit D, et al. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. *Nat Immunol* 2007;8:247–56.
- Radoja N, Gazel A, Banno T, Yano S, Blumenberg M. Transcriptional profiling of epidermal differentiation. *Physiol Genomics* 2006;27:65–78.
- Rossi A, Jang SI, Ceci R, Steinert PM, Markova NG. Effect of AP1 transcription factors on the regulation of transcription in normal human epidermal keratinocytes. *J Invest Dermatol* 1998;110:34–40.
- Rutberg SE, Adams TL, Glick A, Bonovich MT, Vinson C, Yuspa SH. Activator protein 1 transcription factors are fundamental to v-rasHa-induced changes in gene expression in neoplastic keratinocytes. *Cancer Res* 2000;60:6332–8.
- Segre JA, Bauer C, Fuchs E. Klf4 is a transcription factor required for establishing the barrier function of the skin. *Nat Genet* 1999;22:356–60.
- Sen GL, Boxer LD, Webster DE, Bussat RT, Qu K, Zarnegar BJ, et al. ZNF750 is a p63 target gene that induces KLF4 to drive terminal epidermal differentiation. *Dev Cell* 2012;22:669–77.
- Sonder SU, Saret S, Tang W, Sturdevant DE, Porcella SF, Siebenlist U. IL-17-induced NF-kappaB activation via CIKS/Act1: physiologic significance and signaling mechanisms. *J Biol Chem* 2011;286:12881–90.
- Stoll SW, Johnson JL, Li Y, Rittie L, Elder JT. Amphiregulin carboxy-terminal domain is required for autocrine keratinocyte growth. *J Invest Dermatol* 2010;130:2031–40.
- Stoll SW, Rittie L, Johnson JL, Elder JT. Heparin-binding EGF-like growth factor promotes epithelial-mesenchymal transition in human keratinocytes. *J Invest Dermatol* 2012;132:2148–57.
- Stuart PE, Nair RP, Tsoi LC, Tejasvi T, Das S, Kang HM, et al. Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture. *Am J Hum Genet* 2015;97:816–36.
- Sun D, Novotny M, Bulek K, Liu C, Li X, Hamilton T. Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF). *Nat Immunol* 2011;12:853–60.
- Swaidani S, Bulek K, Kang Z, Gulen MF, Liu C, Yin W, et al. T cell-derived Act1 is necessary for IL-25-mediated Th2 responses and allergic airway inflammation. *J Immunol* 2011;187:3155–64.
- Swindell WR, Johnston A, Xing X, Little A, Robichaud P, Voorhees JJ, et al. Robust shifts in S100a9 expression with aging: a novel mechanism for chronic inflammation. *Sci Rep* 2013;3:1215.
- Swindell WR, Sarkar MK, Stuart PE, Voorhees JJ, Elder JT, Johnston A, et al. Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites. *Clin Transl Med* 2015;4:13.
- Swindell WR, Xing X, Stuart PE, Chen CS, Aphale A, Nair RP, et al. Heterogeneity of inflammatory and cytokine networks in chronic plaque psoriasis. *PLoS One* 2012;7(3):e34594.
- Tran QT, Kennedy LH, Leon Carrion S, Bodreddigari S, Goodwin SB, Sutter CH, et al. EGFR regulation of epidermal barrier function. *Physiol Genomics* 2012;44:455–69.
- Truong AB, Kretz M, Ridky TV, Kimmel R, Khavari PA. p63 regulates proliferation and differentiation of developmentally mature keratinocytes. *Genes Dev* 2006;20:3185–97.
- Tsoi LC, Spain SL, Knight J, Ellinghaus E, Stuart PE, Capon F, et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. *Nat Genet* 2012;44:1341–8.
- Uluckan O, Guinea-Viniegra J, Jimenez M, Wagner EF. Signalling in inflammatory skin disease by AP-1 (Fos/Jun). *Clin Exp Rheumatol* 2015;33(4 Suppl. 92):S44–9.
- Van Ruissen F, de Jongh GJ, Zeeuwen PL, Van Erp PE, Madsen P, Schalkwijk J. Induction of normal and psoriatic phenotypes in submerged keratinocyte cultures. *J Cell Physiol* 1996;168:442–52.
- Vermeij WP, Alia A, Backendorf C. ROS quenching potential of the epidermal cornified cell envelope. *J Invest Dermatol* 2011;131:1435–41.
- Vermeij WP, Backendorf C. Skin cornification proteins provide global link between ROS detoxification and cell migration during wound healing. *PLoS One* 2010;5(8):e11957.
- Wallace L, Roberts-Thompson L, Reichelt J. Deletion of K1/K10 does not impair epidermal stratification but affects desmosomal structure and nuclear integrity. *J Cell Sci* 2012;125(Pt. 7):1750–8.
- Wang C, Wu L, Bulek K, Martin BN, Zepp JA, Kang Z, et al. The psoriasis-associated D10N variant of the adaptor Act1 with impaired regulation by the molecular chaperone hsp90. *Nature Immunol* 2013;14:72–81.
- Watt FM. Terminal differentiation of epidermal keratinocytes. *Curr Opin Cell Biol* 1989;1:1107–15.
- Watt FM, Jordan PW, O'Neill CH. Cell shape controls terminal differentiation of human epidermal keratinocytes. *Proc Natl Acad Sci USA* 1988;85(15):5576–80.
- Weaver CT, Elson CO, Fouser LA, Kolls JK. The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin. *Annu Rev Pathol* 2013;8:477–512.
- Wu L, Chen X, Zhao J, Martin B, Zepp JA, Ko JS, et al. A novel IL-17 signaling pathway controlling keratinocyte proliferation and tumorigenesis via the TRAF4-ERK5 axis. *J Exp Med* 2015;212:1571–87.
- Wu L, Zepp J, Li X. Function of Act1 in IL-17 family signaling and autoimmunity. *Adv Exp Med Biol* 2012;946:223–35.
- Zepp J, Wu L, Li X. IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease. *Trend Immunol* 2011;32:232–9.
- Zepp JA, Liu C, Qian W, Wu L, Gulen MF, Kang Z, et al. Cutting edge: TNF receptor-associated factor 4 restricts IL-17-mediated pathology and signaling processes. *J Immunol* 2012;189:33–7.
- Zhu S, Pan W, Shi P, Gao H, Zhao F, Song X, et al. Modulation of experimental autoimmune encephalomyelitis through TRAF3-mediated suppression of interleukin 17 receptor signaling. *J Exp Med* 2010;207:2647–62.